WallStSmart

Honeywell International Inc (HON)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Honeywell International Inc generates 1069% more annual revenue ($37.66B vs $3.22B). WST leads profitability with a 16.9% profit margin vs 10.9%. HON appears more attractively valued with a PEG of 1.97. WST earns a higher WallStSmart Score of 67/100 (B-).

HON

Buy

55

out of 100

Grade: C

Growth: 3.3Profit: 7.0Value: 4.3Quality: 5.0

WST

Strong Buy

67

out of 100

Grade: B-

Growth: 7.3Profit: 8.0Value: 2.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for HON.

WSTSignificantly Overvalued (-32.4%)

Margin of Safety

-32.4%

Fair Value

$185.95

Current Price

$325.92

$139.97 premium

UndervaluedFair: $185.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HON3 strengths · Avg: 8.7/10
Market CapQuality
$135.04B9/10

Large-cap with strong market position

Return on EquityProfitability
24.3%9/10

Every $100 of equity generates 24 in profit

Operating MarginProfitability
21.0%8/10

Strong operational efficiency at 21.0%

WST4 strengths · Avg: 9.0/10
EPS GrowthGrowth
56.1%10/10

Earnings expanding 56.1% YoY

Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.7%8/10

Strong operational efficiency at 21.7%

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

HON4 concerns · Avg: 4.0/10
PEG RatioValuation
1.974/10

Expensive relative to growth rate

P/E RatioValuation
34.0x4/10

Premium valuation, high expectations priced in

Price/BookValuation
9.9x4/10

Trading at 9.9x book value

Revenue GrowthGrowth
2.4%4/10

2.4% revenue growth

WST2 concerns · Avg: 2.0/10
PEG RatioValuation
2.892/10

Expensive relative to growth rate

P/E RatioValuation
41.8x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : HON

The strongest argument for HON centers on Market Cap, Return on Equity, Operating Margin.

Bull Case : WST

The strongest argument for WST centers on EPS Growth, Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : HON

The primary concerns for HON are PEG Ratio, P/E Ratio, Price/Book.

Bear Case : WST

The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 41.8x leaves little room for execution misses.

Key Dynamics to Monitor

HON profiles as a value stock while WST is a growth play — different risk/reward profiles.

WST carries more volatility with a beta of 1.17 — expect wider price swings.

WST is growing revenue faster at 21.0% — sustainability is the question.

WST generates stronger free cash flow (47M), providing more financial flexibility.

Bottom Line

WST scores higher overall (67/100 vs 55/100), backed by strong 16.9% margins and 21.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Honeywell International Inc

INDUSTRIALS · CONGLOMERATES · USA

Honeywell International Inc. is an American publicly traded, multinational conglomerate headquartered in Charlotte, North Carolina. It primarily operates in four areas of business: aerospace, building technologies, performance materials and technologies (PMT), and safety and productivity solutions (SPS).

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?